AstraZeneca PLC (AZN)vsPrime Medicine, Inc. Common Stock (PRME)
AZN
AstraZeneca PLC
$166.08
-0.04%
HEALTHCARE · Cap: $252.33B
PRME
Prime Medicine, Inc. Common Stock
$3.12
-0.64%
HEALTHCARE · Cap: $565.90M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1506554% more annual revenue ($61.37B vs $4.07M). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
PRME
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$166.08
$29.73 discount
Margin of Safety
-42.0%
Fair Value
$2.43
Current Price
$3.12
$0.69 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
No standout strengths identified
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 13.6x book value
3.5% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : PRME
PRME has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : PRME
The primary concerns for PRME are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 2.83 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while PRME is a value play — different risk/reward profiles.
PRME carries more volatility with a beta of 2.35 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 32/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Prime Medicine, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA modifications. The firm has curated a diverse pipeline targeting severe diseases, including genetic disorders and various cancers, addressing substantial unmet medical needs within the healthcare system. With a strong intellectual property foundation and a commitment to developing innovative therapeutic solutions, Prime Medicine is strategically positioned for notable growth and has the potential to significantly change therapeutic approaches in the biopharmaceutical industry.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?